NULISA™ Platform | Immunoassay Analyzers - Alamar Biosciences With single plex up to 7 logs and multiplex up to 12 logs of dynamic range, NULISA enables quantitation across a broad range of biological expression levels without the need for dilution Fully automated workflow with <30 minutes of total hands-on time, can processes up to 288 samples per run batch
NULISA multiplex normalization quality control The scalable, high sensitivity chemistry of the NULISA assay combined with the ARGOTM HT instrumentation provides the ability to focus in on a single target or multiplex hundreds to potentially thousands of targets using one platform for the analysis of protein biomarkers
NULISA: Fully automated ultra- sensitive immunoassay platform for . . . "NULISA platform showed a higher sensitivity for a fair number of analytes and beyond the system's sensitivity, the fact that it comes packaged as an automated platform is attractive, especially given that PEA has historically been a complicated process "
Alamar Biosciences | Ultra-Sensitive Proteomics with the NULISA™ Platform By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next-Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing
CRO – Proteomics – NULISA – Biognosys The NULISA technology by Alamar Corporation integrates a proprietary sequential immunocomplex capture and release workflow with Next-Generation Sequencing (NGS) or qPCR readout to achieve ultra-high sensitivity and scalable multiplexing
NULISA - Argo HT - KCAS Bio This system maintains exceptional performance across formats, from single-plex qPCR to high-plex multiplex NGS analyses, enabling robust, scalable solutions for biomarker discovery, translational programs, and therapeutic monitoring